A roundup of some of the most read news and updates in mantle cell lymphoma in 2020 from CURE®.
There have been several updates in the field of mantle cell lymphoma (MCL) in 2020. Here, CURE® looks back at some of the top news and updates in this field that patients read the most.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
‘Remarkable’ Results from Tecartus in Patients With R/R MCL
January 4th 2024Patients with relapsed/refractory mantle cell lymphoma described by one expert as “older, sicker and more heavily pretreated” than those previously studied experienced impressive responses to treatment with CAR-T cell therapy Tecartus.
Read More